Richard A Goldsmith

This inventor holds 21 USPTO granted patents and 3 published patent applications, plus 3 CIPO patents and 9 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Genentech, Inc., F. Hoffmann-La Roche Ag, Curis, Inc.. Active years: 1999-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Richard A Goldsmith. Retrieved from https://idiyas.com/inventor/richard-a-goldsmith

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 21 (Patent Applications = 3)

% Patents Active = 90.5

CIPO Patents = 3

EPO Patents = 9 (Patent Applications = 6)

Average Co-Inventor Count = 10.6

ph-index = 8

Forward Citations = 192(Granted Patents)

Location History:

Daly City, CA (US) (1999 - 2005)
Belmont, CA (US) (2010 - 2016)
South San Francisco, CA (US) (2011 - 2018)

Company Filing History:

F. Hoffmann-La Roche Ag

Hoffmann-La Roche Inc.

where one patent can have more than one assignee

Years Active: 1999-2018

Loading Chart...

Areas of Expertise:

Pharmaceutical Compounds

PI3K Inhibitors

Benzopyran

Benzoxepin

Hedgehog Signaling

Serine Protease Inhibitors

Oligomers

Quinoxaline

21 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9943519 - Pharmaceutical compounds (2018-04-17),

2. 9487533 - Phosphoinositide 3-kinase inhibitor compounds and methods of use (2016-11-08),

3. 9309265 - Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use (2016-04-12),

4. 9175009 - Benzoxepin PI3K inhibitor compounds and methods of use (2015-11-03),

5. 8993563 - Phosphoinositide 3-kinase inhibitor compounds and methods of use (2015-03-31),

6. 8952043 - Benzoxepin PI3K inhibitor compounds and methods of use (2015-02-10),

7. 8846762 - Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use (2014-09-30),

8. 8802670 - Pharmaceutical compounds (2014-08-12),

9. 8673952 - Benzoxepin PI3K inhibitor compounds and methods of use (2014-03-18),

10. 8450315 - Phosphoinositide 3-kinase inhibitor compounds and methods of use (2013-05-28),

11. 8399690 - 4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulene compounds (2013-03-19),

12. 8383620 - Phosphoinositide 3-kinase inhibitor compounds and methods of use (2013-02-26),

13. 8273743 - Quinoxaline inhibitors of the hedgehog signalling (2012-09-25),

14. 8263633 - Benzoxepin PI3K inhibitor compounds and methods of use (2012-09-11),

15. 8101610 - Bisamide inhibitors of hedgehog signaling (2012-01-24),

Title: Richard A. Goldsmith: Innovator in Pharmaceutical Compounds

Introduction

Richard A. Goldsmith, based in Daly City, CA, has made significant contributions to the field of pharmaceuticals with an impressive portfolio of 21 patents. His innovative work mainly revolves around the development of pharmaceutical compounds that target lipid kinases, showcasing his commitment to enhancing medical treatments for disorders such as cancer.

Latest Patents

Goldsmith's recent patents include groundbreaking pharmaceutical compounds formulated to inhibit lipid kinases, particularly PI3K. One notable patent describes compounds of Formulae Ia, along with their stereoisomers, geometric isomers, tautomers, solvates, metabolites, and pharmaceutically acceptable salts. These compounds are instrumental in diagnosing, preventing, and treating disorders mediated by lipid kinases in mammalian cells.

Another significant patent emphasizes phosphoinositide 3-kinase inhibitor compounds with specific structures, including Formulas Ia-d, where X is S or O, mor is a morpholine group, and R is a monocyclic heteroaryl group. This innovation serves to modulate the activity of lipid kinases and further advances treatment options for cancers related to these enzymes.

Career Highlights

Goldsmith has contributed his expertise to renowned companies such as Genentech, Inc. and F. Hoffmann-La Roche AG. His tenure at these establishments allowed him to collaborate on cutting-edge research and development in the pharmaceutical sector, ultimately leading to his vast collection of patents.

Collaborations

Throughout his career, Richard A. Goldsmith has worked alongside talented individuals such as Alan G. Olivero and Adrian Folkes. These collaborations have enriched his research and helped propel innovative ideas into practical applications within the pharmaceutical industry.

Conclusion

In summary, Richard A. Goldsmith stands out as an influential inventor in the pharmaceutical realm, particularly noted for his work on inhibitors of lipid kinases. His 21 patents reflect a dedication to advancing medical science and improving treatment options for serious conditions like cancer. As he continues to innovate, the impact of his work will likely resonate across the medical community for years to come.

Profile summary based on public USPTO records.